We have presented, together with five other European organizations -MĂ©decins du Monde (MdM), MĂ©decins Sans FrontiĂ¨res (MSF), AIDES (France), Access to Medicines Ireland, Praksis (Greece) â€“ an appeal against the decision in September of the European Patent Office (EPO) to maintain the patent of the US pharmaceutical company Gilead Science on sofosbuvir, a key drug for hepatitis C. We ask the European Patent Office (EPO) to revoke Gileadâ€™s patent because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.
The appeal comes exactly five years after sofosbuvir was first approved for use, in the US, where Gilead launched the drug at US$1,000 per pill, or $84,000 for a 12-week treatment course. The corporation has made more than $10 billion in profit from sales of the drug in the last five years.
In March 2017, 33 civil society organisations from 17 European countries filed a challenge against Gileadâ€™s patent on the base compound of sofosbuvir, stating that Gileadâ€™s patent claims were not legitimate, primarily because they lack inventiveness.
Gileadâ€™s monopoly on sofosbuvir in Europe has allowed the corporation to charge excessive prices for the drug. In some European countries, Gilead charges as much as 43,000 euros for a twelve-week treatment course, when generic versions of the same course can be purchased for less than 75 euros outside of Europe. These exorbitant prices have forced health systems to ration sofosbuvir, leaving thousands of people in Europe with hepatitis C without treatment.
However, despite compelling arguments presented by the organisations opposing the patent, on 14 September 2018, the EPO decided to uphold Gileadâ€™s patent, thereby making it impossible to produce or sell affordable generic versions of the drug in Europe.
“The European Patent Office should revoke this patent and avoid monopolies in medicines that, in addition, have been developed with an important part of public money, as we have been denouncing for some time,” recalls Vanessa LĂłpez, director of Health by Law. “The high price of this and other drugs is putting the sustainability of our health system at risk. So much so that, in Spain, until last year, treatments were rationed and only offered to people in the most advanced stages of the disease. What will happen to the new innovative drugs that are to come?”
â€śThe EPO is being too lenient with pharmaceutical corporations, giving them a free pass,â€ť said Olivier Maguet of MdMâ€™s drug pricing campaign. â€śThere needs to be much greater scrutiny in Europe when it comes to determining whether pharmaceutical corporations deserve patents or not; otherwise, unmerited monopolies will continue to result in out-of-control drug prices.â€ť
The appeal aims to put an end to pharmaceutical corporationsâ€™ abuse of medicines patent systems to increase profits â€“ including in countries outside Europe, where patent offices often follow the EPOâ€™s decisions when they examine patents filed by pharmaceutical corporations.. As some new patented drugs â€“ such as those to treat cancer â€“ come to market with price tags reaching 400,000 euros per person, there is an urgent need to reform patent systems so that people have access to the medicines they need to stay healthy and alive.
â€śUnmerited patents in Europe are giving pharmaceutical corporations the monopoly power that allows them to charge exorbitant prices for many lifesaving drugs,â€ť said GaĂ«lle Krikorian, Head of Policy at MSFâ€™s Access Campaign. â€śThe excessive prices Gilead is charging for sofosbuvir have kept this breakthrough medicine away from millions of people with hepatitis C â€“ in Europe and around the world. What is the point of medical innovation if people and health systems cannot afford the products coming out of it?â€ť